| 2026-10-02 | Trial | New trial registered: A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenaga | Trial register ClinicalTrials.gov |
| 2026-09-30 | Trial | New trial registered: Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chr | Trial register ClinicalTrials.gov |
| 2026-09-30 | Trial | New trial registered: Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets | Trial register ClinicalTrials.gov |
| 2026-09-29 | Results | Results posted: Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity | Trial register ClinicalTrials.gov |
| 2026-09-29 | Trial | New trial registered: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or | Trial register ClinicalTrials.gov |
| 2026-09-29 | Trial | New trial registered: A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight | Trial register ClinicalTrials.gov |
| 2026-09-29 | Trial | New trial registered: SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to | Trial register ClinicalTrials.gov |
| 2026-09-25 | Trial | New trial registered: Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants | Trial register ClinicalTrials.gov |
| 2026-09-23 | Trial | New trial registered: A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects. | Trial register ClinicalTrials.gov |
| 2026-09-18 | Warning letter | FDA warning letter to Empower Clinic Services, LLC dba Empower Pharmacy: CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Regulator FDA warning letters |
| 2026-09-15 | Results | Results posted: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Trial register ClinicalTrials.gov |
| 2026-09-15 | Trial | New trial registered: Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer | Trial register ClinicalTrials.gov |
| 2026-09-15 | Trial | New trial registered: Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial | Trial register ClinicalTrials.gov |
| 2026-09-14 | Trial | New trial registered: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Trial register ClinicalTrials.gov |
| 2026-09-14 | Trial | New trial registered: Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide | Trial register ClinicalTrials.gov |
| 2026-09-10 | Trial | New trial registered: A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) | Trial register ClinicalTrials.gov |
| 2026-09-03 | Trial | New trial registered: Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Trial register ClinicalTrials.gov |
| 2026-09-01 | Trial | New trial registered: Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus | Trial register ClinicalTrials.gov |
| 2026-08-31 | Results | Results posted: Body Surface Gastric Mapping in Patients on Semaglutide | Trial register ClinicalTrials.gov |
| 2026-08-25 | Trial | New trial registered: A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity | Trial register ClinicalTrials.gov |
| 2026-08-24 | Warning letter | FDA warning letter to NuScience Peptides LLC: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-08-24 | Warning letter | FDA warning letter to Peak Performance Peptides: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-08-24 | Warning letter | FDA warning letter to Peptide Partners LLC: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-08-24 | Warning letter | FDA warning letter to Royal Peptides LLC: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-08-24 | Warning letter | FDA warning letter to TXP Innovations LLC dba Tex Peptides: Unapproved New Drugs/Misbranded | Regulator FDA warning letters |
| 2026-08-21 | Results | Results posted: A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Trial register ClinicalTrials.gov |
| 2026-08-21 | Trial | New trial registered: OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme | Trial register ClinicalTrials.gov |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Recall | FDA recall, Class II: Apollo Care, LLC. Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Regulator FDA enforcement reports |
| 2026-08-19 | Trial | New trial registered: A Retrospective Real-World Cohort Study | Trial register ClinicalTrials.gov |
| 2026-08-19 | Trial | New trial registered: Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes | Trial register ClinicalTrials.gov |
| 2026-08-18 | Trial | New trial registered: Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight | Trial register ClinicalTrials.gov |
| 2026-08-18 | Trial | New trial registered: GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry | Trial register ClinicalTrials.gov |
| 2026-08-18 | Trial | New trial registered: Semaglutide in Youth With Autism Spectrum Disorder | Trial register ClinicalTrials.gov |
| 2026-08-18 | Trial | New trial registered: Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome | Trial register ClinicalTrials.gov |
| 2026-08-17 | Trial | New trial registered: A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity | Trial register ClinicalTrials.gov |
| 2026-08-17 | Trial | New trial registered: Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromata | Trial register ClinicalTrials.gov |
| 2026-08-14 | Results | Results posted: Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Trial register ClinicalTrials.gov |
| 2026-08-12 | Trial | New trial registered: HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide | Trial register ClinicalTrials.gov |
| 2026-08-10 | Results | Results posted: A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE) | Trial register ClinicalTrials.gov |
| 2026-08-10 | Trial | New trial registered: Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults | Trial register ClinicalTrials.gov |
| 2026-08-07 | Trial | New trial registered: Comparing Facial Aging Between Identical Twins With 3D Imaging | Trial register ClinicalTrials.gov |
| 2026-08-04 | Trial | New trial registered: A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Trial register ClinicalTrials.gov |
| 2026-08-04 | Trial | New trial registered: A Study of BGM0504 in Early T2DM With Obesity | Trial register ClinicalTrials.gov |
| 2026-08-03 | Results | Results posted: Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects | Trial register ClinicalTrials.gov |
| 2026-08-03 | Trial | New trial registered: GLP-1s in Hip and Knee Arthroplasty | Trial register ClinicalTrials.gov |
| 2026-07-31 | Trial | New trial registered: Tirzepatide Impact Assessment Study | Trial register ClinicalTrials.gov |
| 2026-07-30 | Label | FDA label revised: Ozempic (NDA209637) | Regulator FDA drug label register |
| 2026-07-29 | Federal Register | Federal Register notice: Product-Specific Guidances; Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2026-07-28 | Trial | New trial registered: Semaglutide for Low Back Pain | Trial register ClinicalTrials.gov |
| 2026-07-28 | Trial | New trial registered: Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial | Trial register ClinicalTrials.gov |
| 2026-07-28 | Trial | New trial registered: Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies | Trial register ClinicalTrials.gov |
| 2026-07-27 | Trial | New trial registered: Myocardial Metabolic Flux in Pulmonary Arterial Hypertension | Trial register ClinicalTrials.gov |
| 2026-07-27 | Trial | New trial registered: Preoperative Semaglutide Prior to Radical Prostatectomy | Trial register ClinicalTrials.gov |
| 2026-07-27 | Trial | New trial registered: A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity | Trial register ClinicalTrials.gov |
| 2026-07-24 | Trial | New trial registered: A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) a | Trial register ClinicalTrials.gov |
| 2026-07-22 | Trial | New trial registered: Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy | Trial register ClinicalTrials.gov |
| 2026-07-20 | Trial | New trial registered: Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treate | Trial register ClinicalTrials.gov |
| 2026-07-19 | Trial | New trial registered: Bariatric Surgery Combined With GLP-1RA: A Multicenter Study. | Trial register ClinicalTrials.gov |
| 2026-07-17 | Trial | New trial registered: Effects of GLP-1 RAs on Human Lactation Outcomes | Trial register ClinicalTrials.gov |
| 2026-07-14 | Trial | New trial registered: Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists | Trial register ClinicalTrials.gov |
| 2026-07-14 | Trial | New trial registered: Salivary Function and Dental Changes During GLP-1 Therapy | Trial register ClinicalTrials.gov |
| 2026-07-14 | Trial | New trial registered: Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity? | Trial register ClinicalTrials.gov |
| 2026-07-14 | Trial | New trial registered: Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity | Trial register ClinicalTrials.gov |
| 2026-07-10 | Trial | New trial registered: Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy | Trial register ClinicalTrials.gov |
| 2026-07-10 | Trial | New trial registered: Imaging in Semaglutide Study | Trial register ClinicalTrials.gov |
| 2026-07-02 | Results | Results posted: Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists | Trial register ClinicalTrials.gov |
| 2026-07-01 | Trial | New trial registered: Free Fatty Acid Effects In Type 2 Diabetes | Trial register ClinicalTrials.gov |
| 2026-06-29 | Trial | New trial registered: Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants | Trial register ClinicalTrials.gov |
| 2026-06-26 | Federal Register | Federal Register notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comm | Regulator Federal Register |
| 2026-06-25 | Trial | New trial registered: A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide | Trial register ClinicalTrials.gov |
| 2026-06-25 | Trial | New trial registered: A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Trial register ClinicalTrials.gov |
| 2026-06-24 | Trial | New trial registered: GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation | Trial register ClinicalTrials.gov |
| 2026-06-23 | Trial | New trial registered: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already U | Trial register ClinicalTrials.gov |
| 2026-06-17 | Trial | New trial registered: Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Th | Trial register ClinicalTrials.gov |
| 2026-06-17 | Trial | New trial registered: Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. | Trial register ClinicalTrials.gov |
| 2026-06-16 | Trial | New trial registered: Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease | Trial register ClinicalTrials.gov |
| 2026-06-11 | Trial | New trial registered: Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy | Trial register ClinicalTrials.gov |
| 2026-06-10 | Trial | New trial registered: A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Trial register ClinicalTrials.gov |
| 2026-06-08 | Trial | New trial registered: GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | Trial register ClinicalTrials.gov |
| 2026-06-08 | Warning letter | FDA warning letter to Altru Telehealth, LLC dba Altru Telehealth: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to Amie Health, Inc. dba Amie: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to Clover Meds LLC dba Clover Meds: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to D&H Medical Services: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to Eden Health International Inc. dba Eden: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to Ezra Holdco LLC dba Ezra: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to FITISH: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to FitRX, LLC dba AM RX: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to Glow Medispa, LLC dba Mint Med: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to HydraMed IV LLC dba HydraMed: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-08 | Warning letter | FDA warning letter to Joi and Blokes dba Joi + Blokes: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |